Evidence map›Paper›PMID 17257432›Full record

ArticleBMC molecular biology2007

Reduction of gene repair by selenomethionine with the use of single-stranded oligonucleotides.

Timothy R Schwartz, Eric B Kmiec

Open access · hybridAbstract read
In one paragraph

Article in BMC molecular biology, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
1.4field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 7 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 2 institutions in 1 country.

Timothy R SchwartzDepartment of Biological Sciences, University of Delaware, Delaware Biotechnology Institute, 15 Innovation Way Newark, DE 19711, USA. tischwar@udel.edu <tischwar@udel.edu>
Eric B Kmiec
Biotechnology Institute · USUniversity of Delaware · US

Funding

NCI NIH HHS NIH-R01CA89235
6 · The paper itself

Abstract

backgroundThe repair of single base mutations in mammalian genes can be directed by single-stranded oligonucleotides in a process known as targeted gene repair. The mechanism of this reaction is currently being elucidated but likely involves a pairing step in which the oligonucleotide align in homologous register with its target sequence and a correction step in which the mutant base is replaced by endogenous repair pathways. This process is regulated by the activity of various factors and proteins that either elevate or depress the frequency at which gene repair takes place.

resultsIn this report, we find that addition of selenomethionine reduces gene repair frequency in a dose-dependent fashion. A correlation between gene repair and altered cell cycle progression is observed. We also find that selenium induces expression of Ref-1 which, in turn, modifies the activity of p53 during the cell cycle.

conclusionWe can conclude from the results that the suppression of gene repair by introduction of selenomethionine occurs through a p53-associated pathway. This result indicates that the successful application of gene repair for treatment of inherited disorders may be hampered by indirect activation of endogenous suppressor functions.

Indexed as

DNA RepairTargeted Gene RepairBase SequenceCell CycleCell Line, TumorDNA-(Apurinic or Apyrimidinic Site) LyaseDNA Breaks, Double-StrandedDNA, Single-StrandedGreen Fluorescent ProteinsHumansModels, BiologicalMolecular Sequence DataOligonucleotidesSeleniumSelenomethionineTumor Suppressor Protein p53APEX1 protein, humanDNA-(Apurinic or Apyrimidinic Site) LyaseDNA, Single-StrandedGreen Fluorescent ProteinsOligonucleotidesSeleniumSelenomethionineTumor Suppressor Protein p53

Identifiers

PMID17257432
PMCPMC1797052
OpenAlexW1594556648

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.